Showing results (501-510 of 555) with videos related to
Sort By:
Pageof 56
Molecular Psychiatry|April 28, 2001
Allelic variation of serotonin transporter expression is associated with depression in Parkinson's diseaseR Mössner, A Henneberg, A Schmitt, et al.Alcohol and Alcoholism (Oxford, Oxfordshire)|January 5, 2001
Immunoreactivity of cAMP response element binding protein is not altered in the post-mortem cerebral cortex or cerebellum of alcoholicsM Yamamoto, S Pohli, N Durany, et al.Brain Research|March 22, 2001
Increased levels of calcium-sensitive adenylyl cyclase subtypes in the limbic system of alcoholics: evidence for a specific role of cAMP signaling in the human addictive brainM Yamamoto, S Pohli, N Durany, et al.Brain : a Journal of Neurology|December 1, 1992
Fronto-striatal cognitive deficits at different stages of Parkinson's diseaseA M Owen, M James, P N Leigh, et al.Brain : a Journal of Neurology|April 20, 2004
Neural correlates associated with impaired disgust processing in pre-symptomatic Huntington's diseaseA Hennenlotter, U Schroeder, P Erhard, et al.Movement Disorders : Official Journal of the Movement Disorder Society|January 1, 1989
The antiparkinsonian actions and pharmacokinetics of transdermal (+)-4-propyl-9-hydroxynaphthoxazine (+PHNO): preliminary resultsR J Coleman, K W Lange, N P Quinn, et al.Journal of Psychopharmacology (Oxford, England)|July 19, 2008
Reduced memory and attention performance in a population-based sample of young adults with a moderate lifetime use of cannabis, ecstasy and alcoholF Indlekofer, M Piechatzek, M Daamen, et al.Journal of Neural Transmission (Vienna, Austria : 1996)|January 18, 2008
Children and adolescents with obsessive-compulsive disorder and comorbid attention-deficit/hyperactivity disorder: preliminary results of a prospective follow-up studyS Walitza, H Zellmann, B Irblich, et al.Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|December 1, 1987
Human brain D1 and D2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's, and Huntington's diseasesP Seeman, N H Bzowej, H C Guan, et al.Revue Medicale Suisse|June 22, 2006
[Therapeutic drug monitoring (TDM) of psychotropic drugs: a consensus guideline of the AGNP-TDM group]P Baumann, C Hiemke, S Ulrich, et al.Pageof 56